Abstract: The present invention relates to a composition for preventing or treating obesity or sarcopenia, containing ATPase inhibitory factor 1 (IF1) and, more specifically, to a pharmaceutical composition and a food for preventing or treating obesity or sarcopenia, containing, as an active ingredient, IF1 having an effect of suppressed appetite or effects increased muscle mass and muscle production. According to the present invention, ATPase inhibitory factor 1 (IF1) exhibits, in an obesity-induced mouse model, effects of inhibited weight gain and decreased dietary intake without side effects, and exhibits, in obesity-induced or aged mouse, effects of increased muscle mass, increased muscle protein and muscle production, and thus is very useful as an agent for preventing, alleviating or treating metabolic diseases such as obesity, an agent for suppressing appetite and an agent for preventing, alleviating or treating muscle loss-related diseases such as sarcopenia.

Abstract: The present invention relates to: a method for producing hydrogel microbeads capable of magnetic actuation for the delivery of a therapeutic substance; hydrogel microbeads produced thereby; and a pharmaceutical composition for treating musculoskeletal disorders, comprising same. The method includes the steps of: (a) producing microbeads by electrospinning a mixed solution including sodium alginate, a biocompatible polymer, and magnetic particles; (b) curing the microbeads through ionic crosslinking; and (c) freeze-drying the cured microbeads.

Abstract: The present invention relates to a continuously variable transmission, and more specifically, to a continuously variable transmission that prevents power cut-off when shifting and minimizes a load/impact due to the shifting, and that includes an eccentric disk and an output shaft which rotate in the same direction to prevent noise/vibration/impact that is generated particularly when the eccentric disk that operates a link actuator and the output shaft rotate in opposite directions.

Abstract: The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Abstract: The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Abstract: The present invention relates to a pharmaceutical composition which is for preventing or treating obesity, and comprises a biglycan as an active ingredient. Biglycan according to the present invention suppresses appetite by decreasing the expression of Agrp and NPY, which are appetite promoting peptides, and increasing the expression of POMC, which is an appetite suppressing peptide, and thus is very useful as a medicine for treating obesity.

Abstract: Described herein is a sesquiterpene derivative or a pharmaceutically acceptable salt thereof, a composition for preventing, ameliorating or treating sarcopenia, including the derivative or salt thereof as an active ingredient, and the like. The sesquiterpene derivative or pharmaceutically acceptable salt thereof inhibits increases in the production and mRNA expression of a myostatin protein, which directly affects muscle loss and reduced muscle strength, and thus may exhibit a more fundamental effect of preventing or treating sarcopenia.

Abstract: Provided are a method for preparing chiral nitro derivatives using organic chiral catalyst compounds and water as an eco-friendly solvent, and the like. The catalyst is an organic catalyst based on (R,R)-1,2-diphenylethylenediamine (DPEN), and can prepare nitro derivatives having enantioselectivity and diastereoselectivity in excellent yield through a hydrophobic hydration effect. In particular, the preparation method of the present disclosure can stabilize a transition state through an interfacial reaction between the catalyst and water. In addition, indole derivatives can be synthesized using the chiral nitro derivatives prepared according to the present disclosure to be usefully used for the prevention or treatment of brain-nervous system diseases including depression and muscular diseases including cachexia.

Abstract: Provided are a method for preparing chiral maleimide derivatives using (R,R)-1,2-diphenylethylenediamine (DPEN)-based organic chiral catalyst compounds and water as an eco-friendly solvent, and the like. It is possible to prepare chiral maleimide derivatives having high enantioselectivity even with a small amount of catalyst in an excellent yield within a short time. In particular, the preparation method of the present disclosure can stabilize a transition state through an interfacial reaction between the catalyst and water. In addition, spironolactone derivatives are synthesized using chiral maleimide derivatives prepared according to the present disclosure to be usefully used for the treatment of edema control, heart failure, liver cirrhosis, electrolyte abnormalities, hypertension, etc.

Abstract: According to an embodiment of the present invention, provided is a composition for preventing or treating sarcopenia containing a non-natural amino acid derivative as an active ingredient.

Abstract: According to one embodiment of the present invention, provided is a composition for preventing or treating sarcopenia, containing, as an active ingredient, at least one type of unnatural amino acid selected from the group consisting of D-leucine, D-alanine and D-proline.

Abstract: The present invention relates to a pharmaceutical composition which is for preventing or treating obesity, and comprises a biglycan as an active ingredient. Biglycan according to the present invention suppresses appetite by decreasing the expression of Agrp and NPY, which are appetite promoting peptides, and increasing the expression of POMC, which is an appetite suppressing peptide, and thus is very useful as a medicine for treating obesity.

Abstract: The present invention relates to a composition for preventing or treating obesity or sarcopenia, containing ATPase inhibitory factor 1 (IF1) and, more specifically, to a pharmaceutical composition and a food for preventing or treating obesity or sarcopenia, containing, as an active ingredient, IF1 having an effect of suppressed appetite or effects increased muscle mass and muscle production. According to the present invention, ATPase inhibitory factor 1 (IF1) exhibits, in an obesity-induced mouse model, effects of inhibited weight gain and decreased dietary intake without side effects, and exhibits, in obesity-induced or aged mouse, effects of increased muscle mass, increased muscle protein and muscle production, and thus is very useful as an agent for preventing, alleviating or treating metabolic diseases such as obesity, an agent for suppressing appetite and an agent for preventing, alleviating or treating muscle loss-related diseases such as sarcopenia.

Abstract: The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Abstract: An electric vehicle charging control system may include an electric vehicle which extracts current time information, the integrity of which has been verified, by use of a public key cryptography, and charges power from a charging terminal, when it is determined that a charging contact certificate is valid, based on the extracted current time information, a server to transmit the current time information, the integrity of which has been verified using the public key cryptography, to the electric vehicle, and the charging terminal connected to the electric vehicle. The validity of the certificate used in vehicle charging and billing for charging is determined through the power line communication, and the security against the hacking is enhanced in the charging of the electric vehicle.

Abstract: The present invention relates to a pharmaceutical composition containing ATPase inhibitor factor 1 (ATPIF1) as an active ingredient for the prevention or treatment of diabetes or diabetic complications, and to a pharmaceutical composition containing ATP1F1 as an active ingredient for prevention or treatment of obesity. The composition containing ATPIF1, according to the present invention, has a diabetes treatment effect by promoting sugar absorption in muscle cells and improving insulin sensitivity, and has an obesity prevention or treatment effect by effects of suppressing fat synthesis in fat cells and promoting the browning of fat cells.

Abstract: An electric vehicle charging control system may include an electric vehicle which extracts current time information, the integrity of which has been verified, by use of a public key cryptography, and charges power from a charging terminal, when it is determined that a charging contact certificate is valid, based on the extracted current time information, a server to transmit the current time information, the integrity of which has been verified using the public key cryptography, to the electric vehicle, and the charging terminal connected to the electric vehicle. The validity of the certificate used in vehicle charging and billing for charging is determined through the power line communication, and the security against the hacking is enhanced in the charging of the electric vehicle.

Abstract: The present invention relates to a pharmaceutical composition containing ATPase inhibitor factor 1 (ATPIF1) as an active ingredient for the prevention or treatment of diabetes or diabetic complications, and to a pharmaceutical composition containing ATP1F1 as an active ingredient for prevention or treatment of obesity. The composition containing ATPIF1, according to the present invention, has a diabetes treatment effect by promoting sugar absorption in muscle cells and improving insulin sensitivity, and has an obesity prevention or treatment effect by effects of suppressing fat synthesis in fat cells and promoting the browning of fat cells.

Abstract: The present disclosure relates to a pharmaceutical composition for inducing an exercise mimetic effect, which contains an ?1-adrenergic receptor agonist as an active ingredient, and a method for screening a drug for inducing an exercise mimetic effect using the ?1-adrenergic receptor agonist. The ?1-adrenergic receptor agonist of the present disclosure increases the expression of p-AMPK, PPAR? and PGC-1?, which play key roles in maintaining and regulating energy metabolic activity in vivo, thereby increasing glucose uptake into skeletal muscle cells, suppressing adipocyte differentiation and lipid accumulation, reducing abdominal fat and body weight as well as regulating mitochondrial metabolic disorders and suppressing inflammatory responses. Accordingly, the ?1-adrenergic receptor agonist can be usefully used to prevent and treat diseases requiring AMPK activation (metabolic diseases, cardiovascular diseases, inflammatory disease, etc.).

Abstract: The present disclosure relates to a pharmaceutical composition for inducing an exercise mimetic effect, which contains an ?1-adrenergic receptor agonist as an active ingredient, and a method for screening a drug for inducing an exercise mimetic effect using the ?1-adrenergic receptor agonist. The ?1-adrenergic receptor agonist of the present disclosure increases the expression of p-AMPK, PPAR? and PGC-1?, which play key roles in maintaining and regulating energy metabolic activity in vivo, thereby increasing glucose uptake into skeletal muscle cells, suppressing adipocyte differentiation and lipid accumulation, reducing abdominal fat and body weight as well as regulating mitochondrial metabolic disorders and suppressing inflammatory responses. Accordingly, the ?1-adrenergic receptor agonist can be usefully used to prevent and treat diseases requiring AMPK activation (metabolic diseases, cardiovascular diseases, inflammatory disease, etc.).